DigiTrends’ Post

In a risk-averse industry, I've always admired Sanofi for putting its foot forward into innovation. Tomorrow's webinar is a great opportunity to hear directly from Sanofi leaders about how they are #ReducingCosts + improving internal #efficiencies, all while maintaining quality across their translations globally. Learn more, and save your spot here: https://lnkd.in/eXVV6dwu

FIRST HALF OF 2024: IMEXPHARM ACHIEVES POSITIVE BUSINESS RESULTS, OVERCOMING INDUSTRY CHALLENGES 👍Despite the difficulties faced by the pharmaceutical industry in the first half of the year, with declining purchasing power and rising input costs, Imexpharm successfully "rode the waves," recording positive business results. The company not only maintained its leading position in the production and distribution of high-quality antibiotics but also affirmed its strength in the ETC channel. 📌 Mr. Nguyen An Duy, CFO of Imexpharm, shared at the investor and analyst meeting on August 5th: "1H2024 has proven Imexpharm's resilience as it performed solidly in varying market conditions, while poised for tremendous growth in both domestic and international markets." Let's review Imexpharm's business results achieved in the first half of 2024 through the following video: IMP – Capitalizing on leadership aligning for growth #IMP #Imexpharm #EUGMP #Vungbuoctienphong #ProudofImexpharm #Chatluonghangdau #Tieuchuanchauau

Launching a pharma product in your country and feeling unsure which KPIs to select...? You’re not alone, we often hear participants at our "Effectively Leading Country Launches in Pharma" course say they find this challenging! Yet incorporating the right KPIs is essential for a successful brand launch. 😅 Luckily, we’ve got you covered with some great insights today from CELforPharma faculty member and launch expert Jo Lopez! 👉 Swipe left for best practices in selecting those indicators that will ensure strategic alignment and operational success - ensuring your country-level launch stays on course. 🚀 -------- ☝️ I am Inge 🔥 My mission: Helping Pharma managers acquire business-critical competencies to make better decisions Liked this post? Want to see more? 🔔 Ring the bell on my Profile to get notified 🔝 Connect with me #pharma #launchexcellence #launch #pharmamarketing Uptake

𝗣𝗵𝗮𝗿𝗺𝗮𝗽𝗿𝗼𝗰𝗲𝘀𝘀 🤝 𝗣𝗵𝗮𝗿𝗺𝗮𝗔𝗰𝘁𝗶𝘃𝗲 The #agreement we signed this week with PharmaActive marks a significant milestone in strengthening our presence in the global #pharmamarket, developing our business in MENA Region. 🌍🚀 We firmly believe that this #partnership will enable us to further enhance our international growth, offering #innovative and #cuttingedge solutions to our customers💫 #Pharmaprocess #PharmaActive #internationalpartnership

Pharma More is Your Trusted Partner for Growth in MEA Region

👆Addressing Growth Challenges at Iphamar™: Exploring Partnerships As we continue to expand, we're facing a few key challenges that present exciting opportunities for collaboration: 1. Meeting Growing Demand: The increasing demand for our products is pushing us to explore new ways to scale efficiently. 2. Limited Storage Capacity: To maintain our product quality and meet customer needs, we need to enhance our storage solutions. 3. IT Infrastructure: Enhancing our online platform to improve product visibility and create a seamless purchasing experience for customers. 👆We are open to partnerships that can help us overcome these challenges, from scaling up storage capacity to enhancing product visibility through innovative solutions. If your company is interested in collaborating to support our growth, feel free to reach out. #SupplyChainSolutions #PartnershipOpportunities #Pharmaceuticals #HealthTech #Iphamar GSK Sanofi Merck Group Olajumoke Saheed Ikechukwu Ememah Bayer | Pharmaceuticals Jordan Smith, PharmD, AAHIVP, CPGx

Case Study 📔🖊️ Cipla's European Market Expansion 🌍🇪🇺💊 Background⚕️ Cipla, a leading Indian pharmaceutical company, aims to expand its presence in the European Union (EU) market to boost its revenue by 20% in the next three years. The EU's strict regulations, competitive environment, and pricing pressures pose significant challenges to this goal. Key Challenges🔗 1. Regulatory Compliance: High costs and lengthy approval processes. 2. Intense Competition: Dominated by giants like Roche and Novartis. 3. Pricing Pressure: Focus on low-cost healthcare in Europe. 4. Distribution Network: Need for a robust supply chain. 5. R&D Investment: Requirement for innovation to stand out.🧫🧪 Strategic Decisions🌡️👀 1. Entry Strategy: Form partnerships with local firms and consider acquisitions. 2. Product Focus: Prioritize respiratory and oncology treatments.💊 3. Regulatory Approach: Create a dedicated team for fast-tracking approvals. 4. Pricing Model: Adopt value-based pricing.💸💸 5. Branding: Invest in digital marketing and collaborations with healthcare providers. Implementation Plan💻 0-1 Year: Establish alliances, regulatory team, and identify products. 1-2 Years: Begin acquisitions, invest in R&D, and launch marketing campaigns. 2-3 Years: Scale up supply chain and expand product offerings. Conclusion💡💡 With a hybrid entry strategy, targeted product focus, and strategic investments, Cipla can effectively increase its footprint and revenue in the competitive EU market.🇪🇺🌍

𝐒𝐚𝐧𝐨𝐟𝐢 𝐐𝟐 𝟐𝟎𝟐𝟒 𝐄𝐚𝐫𝐧𝐢𝐧𝐠𝐬 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 Sanofi continues demonstrating strong business momentum, with key achievements and strategic advancements highlighted in our Q2 2024 earnings call. 𝑲𝒆𝒚 𝒕𝒂𝒌𝒆𝒂𝒘𝒂𝒚𝒔- 𝐑𝐨𝐛𝐮𝐬𝐭 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐏𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 👉 Achieved 𝐝𝐨𝐮𝐛𝐥𝐞-𝐝𝐢𝐠𝐢𝐭 𝐬𝐚𝐥𝐞𝐬 𝐠𝐫𝐨𝐰𝐭𝐡 at constant exchange rates. 👉𝐃𝐮𝐩𝐢𝐱𝐞𝐧𝐭 𝐬𝐚𝐥𝐞𝐬 𝐬𝐮𝐫𝐩𝐚𝐬𝐬𝐞𝐝 𝐭𝐡𝐞 𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 euros mark in a 𝐬𝐢𝐧𝐠𝐥𝐞 𝐪𝐮𝐚𝐫𝐭𝐞𝐫, driven by robust U.S. performance and international expansion in Japan, China, and Europe. 👉𝐂𝐨𝐧𝐬𝐮𝐦𝐞𝐫 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐎𝐩𝐞𝐥𝐥𝐚 grew by 𝟏𝟎%, with the U.S. wellness brand Qunol as a significant driver. 𝐔𝐩𝐠𝐫𝐚𝐝𝐞𝐝 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞 👉Based on our solid growth in the first half of the year, Sanofi has upgraded our earnings per share guidance for 2024. 𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 👉Continued strong performance from new medicines, including 𝐍𝐞𝐱𝐯𝐢𝐚𝐳𝐲𝐦𝐞 𝐚𝐧𝐝 𝐀𝐋𝐓𝐔𝐕𝐈𝐈𝐈𝐎, especially in the U.S. 👉𝐒𝐚𝐫𝐜𝐥𝐢𝐬𝐚 𝐚𝐧𝐝 𝐁𝐞𝐲𝐟𝐨𝐫𝐭𝐮𝐬 contributing significantly to top-line growth, with Beyfortus expected to 𝐛𝐥𝐨𝐜𝐤𝐛𝐮𝐬𝐭𝐞𝐫 𝐬𝐭𝐚𝐭𝐮𝐬 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 𝐢𝐧 𝟐𝟎𝟐𝟒. in 2024. 👉Exciting progress in our pipeline, including the approval of 𝐃𝐮𝐩𝐢𝐱𝐞𝐧𝐭 𝐟𝐨𝐫 𝐂𝐎𝐏𝐃 in the EU and 𝐀𝐋𝐓𝐔𝐕𝐈𝐈𝐈𝐎 under the name 𝐀𝐥𝐭𝐮𝐯𝐨𝐜𝐭. 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐚𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞𝐬 👉Several regulatory submissions accepted, including priority reviews for 𝐃𝐮𝐩𝐢𝐱𝐞𝐧𝐭 and 𝐒𝐚𝐫𝐜𝐥𝐢𝐬𝐚. 👉Continued advancements in our pipeline and strategic collaborations to drive drug development and innovation. 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐨 𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 👉Recognized by TIME Magazine as the world’s seventh most sustainable company and the top in pharma. 👉On track to achieve 𝐜𝐚𝐫𝐛𝐨𝐧 𝐧𝐞𝐮𝐭𝐫𝐚𝐥𝐢𝐭𝐲 𝐛𝐲 𝟐𝟎𝟑𝟎, with significant progress in reducing carbon emissions across our operations. #Sanofi #Earnings #Healthcare #Innovation #Sustainability #Pharma #BusinessGrowth #ESG #Dupixent #Q2Results

In its pursuit of recognizing excellence in supply chain management, the Institute of Supply Chain Management diligently evaluated over a hundred listed pharmaceutical companies to identify the sector's champions. Through meticulous analysis of annual reports and publicly available data, ISCM's research team assessed these firms' supply chain efficiency. The upcoming India Supply Chain Thought Leadership Summit in September promises to unveil the top 30 Supply Chain Champions, including sectoral leaders. This exercise for the pharmaceutical sector is a precursor to ISCTLS. We will be unveiling these rankings on 8th April at The 3rd Pharma SCMLOG summit at Courtyard by Marriott. Such rankings reflect ISCM's commitment to recognizing and celebrating outstanding contributions to supply chain management. We invite leaders and the supply chain community to participate write to events@iscmforums.com for attending the same. More info: https://pharmascmlog.com/ Aarti Industries Ltd. Abbott ACG World Strides Ami Lifesciences Pvt. Ltd. Biocon Cipla ERIS LifeScience WorldWide Fermenta Biotech Limited Biotech Healthcare Intas Pharmaceuticals IOL Chemicals and Pharmaceuticals Limited Johnson & Johnson MANKIND PHARMA LTD Merck Group Reliance Retail Teva Pharmaceuticals Thermo Fisher Scientific Zuventus Healthcare Limited, Mumbai Torrent Pharmaceuticals Ltd Cipla Laurus Labs Limited Dr. Reddy's Laboratories Zydus Group Lupin SUN PHARMA Alembic Pharmaceuticals Limited Glenmark Pharmaceuticals AUROBINDO PHARMA LTD Ipca Laboratories Limited Granules India Limited Pfizer Ajanta Pharma Ltd Morepen Laboratories Limited India GSK Gland Pharma Limited Suven Pharmaceuticals JB Chemicals And Pharma Limited Sanofi #LogisticsLeadership, #EfficientSourcing, #SupplyChainInnovation, #SustainableLogistics, #InventoryOptimization, #GlobalShippingTrends, #SmartWarehousing, #TechDrivenSupplyChain, #DemandForecasting, #ResilientSupplyChain #LogisticsLeadership, #EfficientSourcing #SupplyChainInnovation #SustainableLogistics, #InventoryOptimization, #GlobalShippingTrends, #SmartWarehousing, #TechDrivenSupplyChain #DemandForecasting #ResilientSupplyChain #PharmaSupplyChain, #ColdChainLogistics, #RegulatoryCompliance, #SupplyChainVisibility, #PharmaDistribution, #QualityControl, #DrugTraceability, #ClinicalTrialsLogistics, #HealthcareSupplyChain, #VaccineDistribution #iscm #iacmforums

When launching a pharma brand, the pressure to succeed is immense. 😰 But what does this mean, achieving an excellent brand launch ❓ In this insightful video Jo Lopez, CELforPharma faculty member, launch expert and Practice Lead Early Commercialisation & Launch at Uptake, shares the 6 key outcomes that define a successful launch. 🎯📈 🎬 Watch the video to discover these crucial outcomes and elevate your pharma launch strategy! -------- ☝️ I am Inge 🔥 My mission: Helping Pharma managers acquire business-critical competencies to make better decisions Liked this post? Want to see more? 🔔 Ring the bell on my Profile to get notified 🔝 Connect with me  #pharma #launchexcellence #launch #pharmamarketing Uptake